Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

Aravive (NASDAQ: ARAV) stock up 62% - a truly weird analysis from Zacks

The trigger here seems to be a really odd, odd, piece of analysis from Zacks

Update : 18 Oct 2023, 12:03 PM

Aravive (NASDAQ: ARAV) stock was up 62% yesterday. We generally think of ARAV stock as the bombed out rubble of a pharma development attempt. They did try to develop a drug, it didn’t work. We’re now in that little interregnum while everyone works out what to do next. Without news that no, actually, the drug succeeded there’s little that will lift the stock. Certainly, not much that will lift it 62% in the one day. But clearly it has gone up but why?

The background at Aravive: “Aravive (NASDAQ: ARAV) stock is down 50% this morning. ARAV stock is down because of the announcement last night, after close. Effectively, the drug they’re testing doesn’t work. So, pretty much, that’s that. All that money, just gone. Now this isn’t entirely and wholly true, there may be other cancers it works on and so on but the specific target they were testing for, nope, doesn’t work.” That is a bit brutal but that is pretty much the situation. In development work you raise enough capital to get to the next marker, the next valuation point. If you don’t pass the tests then all the work to then is worthless and the money gone. If you do pass the tests then you raise more money and work towards the next tests.

aravive

Aravive stock price from Google Finance

We also looked more recently at Aravive: “Aravive (NASDAQ: ARAV) stock is up 27% premarket. This looks very hopeful to us in ARAV stock - we think it likely that this will face away. There is always the option that someone is about to ride over the hill and rescue the company but even if that were to happen we think the recovery for equity would be minimal at best.” and “It doesn’t work on what they tested it upon, they need $100 million to test it on renal cancers. They’re laying off staff and talking of at least Chapter 11 if not liquidation. Nope, we don’t see that as being up 27%. A flurry of interest perhaps but not a substantive move in our minds.”

But clearly some disagree and we think it’s from this Zachs report: “Investors might want to bet on Aravive (ARAV), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.” Ummm, OK. “For the fiscal year ending December 2023, this biopharmaceutical company is expected to earn -$1.10 per share, which is a change of 47.6% from the year-ago reported number.”

Zachs is running an automated system without human intervention or editing for sensibility. Aravive will lose less money this year because it will spend less capital upon testing. Because it has stopped testing because the drug doesn’t work. In Zacks’s automated model this is an improvement in earnings and so a positive for the stock price.

We don’t think so, really we don’t.  

Top Brokers